How does dalfampridine help people with MS walk better?
Dalfampridine blocks potassium channels in damaged nerve fibers, allowing electrical signals to travel faster through MS lesions. Clinical trials show 1 in 4 patients walk 25% faster within 2–4 weeks [3].
In multiple sclerosis, the immune system damages myelin—the insulation around nerve fibers in the spinal cord. This damage slows electrical signals that control leg movement. Dalfampridine blocks potassium channels, which normally allow electrical signals to leak out of damaged fibers. By blocking these leaks, the drug lets signals travel faster through the damaged areas, restoring walking speed [3].
Your brain sends electrical impulses down the spinal cord to move your legs. In MS, these impulses get stuck or slow down because the protective coating is damaged. Dalfampridine acts like a patch that stops the electrical signal from leaking out, so it reaches your legs faster and stronger. This is why some patients feel their legs respond more quickly and they can walk without dragging their feet [7].
Not everyone responds equally. About 1 in 4 MS patients experience meaningful walking improvement (a 25% speed increase on the 25-foot walk test). The rest see no benefit or minimal change. Your neurologist can sometimes predict who'll respond by looking at your MS type and how much nerve damage you have. If you don't improve by week 4, stopping is safe and won't cause withdrawal [3].
Ask your neurologist: 'Can you predict if I'm likely to respond based on my MRI or walking test?' If yes, start dalfampridine. If no clear predictor, try it for 4 weeks—if you're not walking faster by then, stop and explore other options like physical therapy or mobility aids.